Classes
DEA Class; Rx
Common Brand Names; Nuplazid
- Antipsychotics, 2nd Generation;
Description
Used for hallucinations and delusions associated with Parkinson’s disease psychosis; not approved for patients with dementia-related behavioral problems unrelated to Parkinson’s disease psychosis
May cause QT prolongation; avoid use with other drugs that prolong the QT interval and avoid in patients with risk factors for QT prolongation
Indications
Indicated for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.
Contraindications
Documented hypersensitivity reaction to drug or components; rash, urticaria, and reactions consistent with angioedema (e.g., tongue swelling, circumoral edema, throat tightness, and dyspnea)
Adverse Effects
Nausea (7%)
Peripheral edema (7%)
Confusional state (6%)
Hallucinations (5%)
Constipation (4%)
Gait disturbance (2%)
Rash
Urticaria
Reactions consistent with angioedema (e.g., tongue swelling, circumoral edema, throat tightness, and dyspnea)
Somnolence, falls
Agitation
Aggression
Warnings
Antipsychotic drugs increase the all-cause risk of death in elderly patients with dementia-related psychosis (see Black Box Warnings)
Pimavanserin is a substrate of CYP3A4; strong CYP3A4 inhibitor or inducers affect systemic exposure (see Dosage Modifications and Interactions)
Pregnancy and Lactation
There are no data for use in pregnant women that would allow assessment of the drug-associated risk of major congenital malformations or miscarriage
Unknown if distributed in human breast milk
Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for the drug, and any potential adverse effects on the breastfed infant from the drug or from the underlying maternal condition
Maximum Dosage
34 mg/day PO.
34 mg/day PO.
Safety and efficacy have not been established.
Safety and efficacy have not been established.
Not indicated.
How supplied
Pimavanserin
capsule
- 34mg
tablet
- 10mg